Best Genomics Companies in Connecticut, United States
The 39 best Genomics companies in Connecticut, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Sema4.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Connecticut
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Sema4 Provider of genome-based diagnostic testing solutions for reproductive health and oncology | $241M | 52 mo ago | 1,200 | — | — | — | — |
| 2 | IsoPlexis Developer of multiplexed single-cell analysis tools for the diagnostics and life science research | $186M | 68 mo ago | 195 | — | — | 72 patents Single-cell immune profiling and multiplexed analysis of cellular therapeutics | — |
| 3 | Transgenomic Molecular Diagnostics in cardiology, oncology, and inherited diseases | $72M | 112 mo ago | 53 | — | — | 51 patents Enrichment and detection of low-frequency DNA variants using cold-PCR for diagnostic sequencing | — |
| 4 | Molecular Staging Transforming detection and measurement of proteins and nucleic acids for life sciences | $50M | 184 mo ago | — | Torben Spanget Christensen ex-CEO | — | — | — |
| 5 | Azitra Developer of micriobiome based therapeutics solution for treating skin atopic dermatitis or eczema | $37M | 68 mo ago | 17 17 → 13 (-24%) | Francisco Salva CEO | DrupalPHPBootstrap+20 | 110 patents Engineered live microbial therapeutics for dermatological disease treatment | — |
| 6 | Ion Torrent Next generation sequencing using semiconductor technology. | $37M | 198 mo ago | — | Jonathan Rothberg Founder & CEO | — | — | — |
| 7 | Tangen Biosciences Developer of a molecular diagnostics platform | $24M | 39 mo ago | 10 | John Davidson Co-Founder | — | — | — |
| 8 | Biological Industries Cell culture media, reagents, and biopreservation solutions for biopharmaceutical research and manufacturing | $11M | 112 mo ago | 5 | — | — | — | — |
| 9 | DotLab Provider of a molecular diagnostic testing tool for endometriosis in women | $10M | 86 mo ago | 11 | Heather Bowerman Founder & CEO | WebflowAmazon Web Servicescore-js+9 | — | — |
| 10 | Bioarray Gene expression- based diagnostics for cancer. | $7M | 107 mo ago | 7 | — | — | 286 patents Multiplexed nucleic acid typing and microparticle array platforms for genetic analysis | — |
| 11 | Mira Dx miRNA-based diagnostic tests | $7M | 192 mo ago | 13 13 → 29 (+123%) | Joanne Weidhaas Chairperson of the Board and Co-Founder | WordPressMySQLPHP+17 | 44 patents Predictive cancer biomarkers for immunotherapy response and radiation toxicity assessment. | — |
| 12 | Mitotherapeutix Developer of small molecules based drug using siRNA technology for various diseases | $5M | 18 mo ago | 5 | Robert Hemley Co-Founder & COO | — | 8 patents Targeted multivalent ligand drug delivery and epigenetic silencing of methylation‑controlled J‑protein. | — |
| 13 | Precipio Diagnostics Provider of cancer diagnostics and second opinion tools | $5M | 106 mo ago | 56 | — | WordPressCart FunctionalityWooCommerce+17 | — | — |
| 14 | RNAConnect Provider of reverse transcriptase solutions for RNA analysis | $4M | 16 mo ago | — | Ryan Muldoon Co-Founder & CEO | Cart FunctionalityShopifyShop Pay+17 | — | 1 launch |
| 15 | Genomas Developer of treatments for CNS disorders and metabolic diseases | $4M | 155 mo ago | — | Gualberto Ruano CEO | — | 15 patents Pharmacogenomic prediction of drug metabolism and adverse metabolic/ cardiovascular effects | — |
| 16 | Intus Bio Developer of sequencing technology for microbiome testing, pathogen identification, and tracking | $3M | 15 mo ago | 9 | Ken Beers CEO | — | — | — |
| 17 | GlyGenix Therapeutics Provider of gene therapies for glycogen storage diseases | $3M | 102 mo ago | — | Barry Schweitzer CEO | — | — | — |
| 18 | Enrich Biosystems Provider of cell therapy development platform services | $2M | 9 mo ago | 17 | Dong Wang Co-founder | WordPressMySQLPHP+21 | — | — |
| 19 | Verinomics Developer of genomic and gene editing platforms for crop improvement | $2M | 17 mo ago | 13 | Stephen Dellaporta Founder | — | — | — |
| 20 | AtlasXomics Provider of omics data analysis platform | $2M | 14 mo ago | 22 22 → 22 (+0%) | — | Cart FunctionalitySquarespace CommerceSquarespace+17 | 13 patents Microfluidic chiplet platforms enabling high‑throughput, spatially encoded tissue assay screening | — |
| 21 | Bactana Corporation Developer of proprietary microbiome technology | $2M | 50 mo ago | 7 | John Kallassy Founder | — | 8 patents Veterinary feed additives and metabolic therapeutics improving poultry safety and efficiency. | — |
| 22 | My Gene Counsel Digital genetic counseling platform bridging genetics and precision medicine | $1M | 100 mo ago | 25 | — | WordPressMySQLPHP+15 | — | 1 job opening |
| 23 | PlumCare Developer of saliva-based DNA testing services to monitor family health | $750K | 102 mo ago | — | Petros Tsipouras CEO | — | — | — |
| 24 | Smpl Bio Provider of bioinformatics platform for genomics and proteomics analysis | $500K | 129 mo ago | — | Edward Hemphill Co-Founder | — | — | — |
| 25 | QCDx Developer of instruments for the detection of rare cells in the blood circulation | $130K | 16 mo ago | 9 | — | — | 23 patents Liquid biopsy diagnostics: detecting circulating tumor cells, viral pathogens, and biomarkers in biological samples. | — |
Top 12 Genomics companies in Connecticut
#1
Series A · Branford, Connecticut · founded 2022 · 17 employees$2.2Mraised▾
Provider of cell therapy development platform services
- Nov 2025Series A$1.4M
- May 2024Series A$2.2M
- Aug 2022Grant (prize money)$1.7M
- Jun 2022Series A$3.8M
#2
Funding Raised · Farmington, Connecticut · founded 2014 · 5 employees$5.2Mraised▾
Mitotherapeutix is a developer of small molecules based drug-using siRNA technology for various diseases. The company target and control the metabolic activity in the mitochondria helping in the treatment of kidney, immune, and liver diseases. The company drug candidates MT-001 to MT004 are in the early stage of the preclinical study. The company is targeting diseases like Unilateral Ureter Obstruction, acute liver failure, CD8 T-cells, and its role in treating diseases like cancer among others. The company is using proprietary technology to target the beta-oxidation pathway in the mitochondria.
- Mar 2025Grant (prize money)$30.9K
- Jan 2025Grant (prize money)$2.1M
- Apr 2023Grant (prize money)$273.9K
- Jun 2021Grant (prize money)$2.1M
#3
Seed · New Haven, Connecticut · founded 2019 · 22 employees$1.8Mraised▾
Provider of omics data analysis platform. It offers a drug discovery platform for clinicians and researchers to analyze multi-omics data like transcriptomic, proteomic, and epigenomics.
- Jun 2025Grant (prize money)$400K
- May 2025Grant (prize money)$399.9K
- Jul 2024Grant (prize money)$399.9K
- Mar 2024Grant (prize money)$400K
#4
Seed · Farmington, Connecticut · founded 2014 · 9 employees$3.1Mraised▾
Developer of sequencing technology for microbiome testing, pathogen identification, and tracking. It offers a platform, called Titan-1 which ses a patented 16S-ITS-23S amplicon to generate information to differentiate strains without sequencing the whole genome.
- May 2025Seed$1.1M
- Jun 2024Conventional Debt—
- Jun 2024Seed$2M
- Nov 2022Seed$1.1M
#5
Funding Raised · Branford, Connecticut · founded 2023$4.1Mraised▾
Provider of reverse transcriptase solutions for RNA analysis. It offers UltraMarathonRT a next-generation, ultra-processive reverse transcriptase that creates full-length cDNAs from any RNA template. It is used for discovery of gene expression, cell, gene, and RNA therapy vaccine, and diagnostics.
- Apr 2025Grant (prize money)$2.5M
- May 2024Grant (prize money)$1.6M
#6
Series A · New Haven, Connecticut · founded 2016 · 13 employees$2Mraised▾
Developer of genomic and gene editing platforms for crop improvement. The company integrates genomics, computational biology, and gene editing into breeding programs. It offers a population genomics platform that deciphers complex genetic traits. The company’s breeding platform optimizes trait development, delivering market-ready specialty crop varieties. It also provides a gene editing platform that enables product development.
- Mar 2025Series A$13M
- Feb 2024Grant (prize money)$250K
- Dec 2018Seed$2M
#7
Public · Stamford, Connecticut · founded 2017 · 1200 employees$241Mraised▾
Provider of genome-based diagnostics solutions for reproductive health and oncology. The company's platform helps physicians and patients to engage health data from genome test results, clinical records, wearable sensor metrics, and other sources. The company also offers a health intelligence platform.
- May 2022Post IPO$200M
- Jul 2020Series C$121M
- Aug 2019Series B$120M
#8
Acquired · New Haven, Connecticut · founded 2012 · 195 employees$185.9Mraised▾
Developer of multiplexed single-cell analysis tools for diagnostics and life science research. Their specialties include 'secretome analysis for applications in immune monitoring, vaccine response evaluation, personalized medicine, adoptive immune therapies, stem cell research, and oncology.
- Jan 2021Conventional Debt$50M
- Jan 2021Series D$92.5M
- Jun 2020Grant (prize money)$2M
- Jan 2020Series C$20M
#9
Series B · Branford, Connecticut · founded 2013 · 10 employees$24.3Mraised▾
Developer of a molecular diagnostics platform. The GeneSpark diagnostic instrument used for the detection of targeted DNAs and RNAs from specimens by using isothermal nucleic acid amplification. The company has a TangenDx assay based on GeneSpark is used for COVID, flu, yeast, bacterial, and AMR bloodstream infection.
- May 2023Series B$464.8K
- Aug 2020Series B$12.2M
- Jul 2020Series B$11.2M
- May 2020Grant (prize money)$3.3M
#10
Seed · Farmington, Connecticut · founded 2016 · 9 employees$130Kraised▾
Developer of instruments for the detection of rare cells in the blood circulation. The products of the company include RareScope a Rare Cell Detection, RarePrep holds cells immobilized in the life-sustaining hydrogel, RarePicker, and RareVivo.
- May 2025Conventional Debt$5.3M
- May 2025Seed$1.7M
- Dec 2017Seed$130K
#11
Public · Farmington, Connecticut · founded 2014 · 17 employees$37.4Mraised▾
Developer of micriobiome based therapeutics solution for treating skin atopic dermatitis or eczema. Its lead product is AZT-04 that helps in treating cancer therapy-associated rashes. It has developed other drug candidates in the preclinical stage are AZT-01 which is filaggrin supplementation through bacterial delivery to treat atopic dermatitis or eczema; ATR-12 which contains a proprietary strain of Staphylococcus epidermidis engineered to express therapeutic LEKTI protein to treat Netherton syndrome among others.
- Jan 2021Series B$1M
- Sep 2020Series B$17M
- Oct 2019Series A$14M
- Apr 2019Grant (prize money)$719.7K
#12
Public · New Haven, Connecticut · founded 1997 · 53 employees$72.2Mraised▾
Transgenomic is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through its proprietary molecular technologies, clinical and research services. The Company's specialty is in cardiac genetic testing with a family of innovative products, including its flagship C-GAAP test designed to detect gene mutations which indicate cardiac disorders, or which can lead to serious adverse events. Transgenomic has three complementary business divisions: Transgenomic Clinical Laboratories, which specializes in molecular diagnostics for cardiology, oncology, neurology, and mitochondrial disorders; Transgenomic Pharmacogenomic Services, a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development; and Transgenomic Diagnostic Tools, which produces equipment, reagents, and other consumables that empower clinical and research applications in molecular testing and cytogenetics.
- Apr 2017Post IPO$1.1M
- Jan 2016Post IPO$2.2M
- Jul 2015Post IPO$3M
- Jan 2015Post IPO$1.7M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Connecticut is moving
A read on the academic research around Bioinformatics in Connecticut — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 43 papers.
- University of Connecticut31
- VA Connecticut Healthcare System5
- Connecticut Agricultural Experiment Station3
- Southern Connecticut State University2
- Connecticut Children\'s Medical Center2
- Genome5
- Gene4
- Function (biology)3
- Microbiome2
- Lung1
- Nucleic acid2
- Phylogenetic network1
- Phylogenetic tree1
- Reticulate evolution1
- Phylogenetics1
- Rimonabant1
- Endocannabinoid system1
- Human studies1
- Preclinical research1
- Cannabidiol1
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.